C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

Group 1 - C4 Therapeutics reported a quarterly loss of $0.35 per share, better than the Zacks Consensus Estimate of a loss of $0.40, and an improvement from a loss of $0.55 per share a year ago, resulting in an earnings surprise of 12.50% [1] - The company posted revenues of $15.36 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 158.10%, compared to revenues of $11.07 million in the same quarter last year [2] - C4 Therapeutics has surpassed consensus EPS estimates two times over the last four quarters, indicating a positive trend in performance [2] Group 2 - The stock has underperformed the market, losing about 2.1% since the beginning of the year, while the S&P 500 has gained 21.9% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates for the coming quarter at -$0.43 on revenues of $7.33 million, and for the current fiscal year at -$1.57 on revenues of $25.66 million [4][7] - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8]